Cell surface heparan sulfate released by Heparanase promotes melanoma cell migration and angiogenesis

Journal of Cellular Biochemistry

Volumn 106, Issue 2, 2009, Pages 200-209

  Roy, Madhuchhanda ^a   Marchetti, Dario ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Heparan sulfate proteoglycans; Heparanase; Melanoma; Migration

Indexed keywords

CHEMOKINE; GROWTH FACTOR; HEPARANASE; PROTEOHEPARAN SULFATE; BETA GLUCURONIDASE; HEPARAN SULFATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; ARMYWORM; CATTLE; CELL MEMBRANE; CELL MOTION; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

MAMMALIA;

ANIMALS; CATTLE; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; MELANOMA; MICE; NEOVASCULARIZATION, PATHOLOGIC; SPODOPTERA;

EID: 61449222897     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22005     Document Type: Article

References (57)

1. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395.
2. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD. 2005. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280:40066-40073.
3. Dempsey LA, Brunn GJ, Platt JL. 2000. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 25:349-351.
4. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. 2006. Heparanase localization and expression by head and neck cancer: Correlation with tumor progression and patient survival. Neoplasia 8:1055-1061.
5. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. 2004. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96:1219-1230.
6. Elkin M, Ilan M, Ishai-Michaeli R, Friedmann Y, Pappo O, Pecker I, Vlodavsky I. 2001. Heparanase as mediator of angiogenesis: Mode of action. FASEB J 15:1661-1663.
7. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest 108:169-173.
8. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Ann Rev Biochem 71:435-471.
9. Ferrara N, Gerber H-P, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676.
10. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
11. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O. 2000. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma: Evidence for Its role in colonic tumorigenesis. Am J Pathol 157:1167-1175.
12. Gallagher JT. 2001. Heparan sulfate: Growth control with a restricted sequence menu. J Clin Invest 108:357-361.
13. Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi BZ, Neufeld G. 1996. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 271:5519-5523.
14. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. 1999. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5:803-809.
15. Ilan N, Elkin M, Vlodavsky I. 2006. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38:2018-2039.
16. Iozzo RV. 2001. Heparan sulfate proteoglycans: Intricate molecules with intriguing functions. J Clin Invest 108:165-167.
17. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. 2003. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63:8749-8756.
18. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
19. Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA. 2002. Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointest Surg 6:167-172.
20. Krufka A, Guimond S, Rapraeger AC. 1996. Two hierarchies of FGF-2 signaling in heparin: Mitogenic stimulation and high-affinity binding/receptor transphosphorylation. Biochemistry 35:11131-11141.
21. Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P. 1999. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commu 261:183-187.
22. Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D. 2006. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem 281:37844-37852.
23. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
24. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. 2002a. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99:568-573.
25. Liu D, Shriver Z, Qi Y, Venkataraman G, Sasisekharan R. 2002b. Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost 67-78.
26. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi J-F, Reme T, Goldschmidt H, Klein B. 2007. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109:4914-4923.
27. Marchetti D. 1997. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases. J Cell Physiol 172:334-342.
28. Marchetti D, Liu S, Spohn WC, Carson DD. 1997. Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate. J Biol Chem 272:15891-15897.
29. Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA, Xu X. 2002. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 132:326-333.
30. McKenzie EA. 2007. Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol 151:1-14.
31. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R, Turner P, Stamps A, McMillan D, Saville G, Ng S, Mason S, Snell D, Schofield D, Gong H, Townsend R, Gallagher J, Page M, Parekh R, Stubberfield C. 2003. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423-435.
32. Menter DG, Herrmann JL, Marchetti D, Nicolson GL. 1994. Involvement of neurotrophins and growth factors in brain metastasis formation. Invasion Metastasis 14:372-384.
33. Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner EF, Orci L. 1990. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435-445.
34. Nakajima M, Irimura T, Nicolson GL. 1988. Heparanases and tumor metastasis. J Cell Biochem 36:157-167.
35. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S, Shridhar V. 2006. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 66:6025-6032.
36. Parish CR, Coombe DR, Jakobsen KB, Bennett FA, Underwood PA. 1987. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int J Cancer 40:511-518.
37. Pervin A, Gallo C, Jandik KA, Han XJ, Linhardt RJ. 1995. Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology 5:83-95.
38. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F. 1997. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272:13390-13396.
39. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. 2006. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 13:1845-1857.
40. Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD, Marchetti D. 2004. Heparanase degrades syndecan-1 and perlecan heparan sulfate: Functional implications for tumor cell invasion. J Biol Chem 279:8047-8055.
41. Reiland J, Kempf D, Roy M, Denkins Y, Marchetti D. 2006. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8:596-606.
42. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. 2006. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 281:1731-1740.
43. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG, Marchetti D. 2005. Antisense-mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia 7:253-262.
44. Sanderson RD, Yang. Y, Kelly T, MacLeod V, Dai Y, Theus A. 2005. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Biol Chem 96:897-905.
45. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. 2002. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521-528.
46. Schlessinger J, Lax I, Lemmon M. 1995. Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 83:357-360.
47. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
48. Sinnappah-Kang ND, Kaiser AJ, Blust BE, Mrak RE, Marchetti D. 2005. Heparanase, TrkC and p75NTR: Their functional involvement in human medulloblastoma cell invasion. Int J Oncol 27:617-626.
49. Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, NakamuraM, Mori I, Kakudo K. 2002. Heparanase: A key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 15:593-598.
50. Terman B, Khandke L, Dougher-Vermazan M, Maglione D, Lassam NJ, Gospodarowicz D, Persico MG, Bohlen P, Eisinger M. 1994. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. Growth Factors 11:187-195.
51. Uno F, Fujiwara T, Takata Y, Ohtani S, Katsuda K, Takaoka M, Ohkawa T, Naomoto Y, Nakajima M, Tanaka N. 2001. Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res 61:7855-7860.
52. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. 1999. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 5:793-802.
53. Vreys V, David G. 2007. Mammalian heparanase: What is the message? J Cell Mol Med 11:427-452.
54. Xu X, Rao G, Quiros RM, Kim AW, Miao H-Q, Brunn GJ, Platt JL, Gattuso P, Prinz RA. 2007. In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas: Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 282:2363-2373.
55. Yang Y, MacLeod V, Miao H-Q, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li J-P, Zcharia E, Vlodavsky I, Sanderson RD. 2007. Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282:13326-13333.
56. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. 2000. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60:4959-4967.
57. Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I, Ilan N. 2003. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63:7733-7741.